Quick Takeaways:
- Dechra received the US FDA approval for Zygolide (pergolide tablets), the first FDA-approved bioequivalent for treating clinical signs of Pituitary Pars Intermedia Dysfunction (PPID) in horses, expanding access to a key therapy for this common endocrine disorder.
- PPID (Equine Cushing’s Disease) impacts ~21% of horses ≥15 years and up to 30% over 30, highlighting the need for accessible treatments. As a generic option, Zygolide offers cost relief while maintaining efficacy, addressing a growing demand as the senior horse population rises.
- Zygolide is designed for improved usability with 360° scored tablets for flexible dosing, protective packaging for stability, and a peppermint flavor to ease administration, enhancing the treatment experience for both horses and caretakers. The therapy will be available via veterinarians starting January 2026.
Why It Matters?
Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses.
The focus on flexible dosing and palatability makes long-term therapy more practical in the field, strengthening Dechra’s position in equine endocrinology and chronic care.
Source: Businesswire | Image: Dechra
